Lupin Limited has informed the Exchange regarding a press release dated April 02, 2026, titled "Lupin Completes Acquisition of VISUfarma".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin has completed the acquisition of VISUfarma B.V., a European specialty pharmaceutical company focused on ophthalmology, from private equity firm GHO Capital Partners. The deal adds over 60 branded products to Lupin's eye care portfolio, spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma generated €53 million in revenue in 2025 and has a strong commercial presence in Italy, the UK, Spain, Germany, and France. The acquisition marks a key step in Lupin's strategy to grow its specialty care business and expand its footprint in Europe. CEO Vinita Gupta described the deal as immediately accretive to earnings.
This is a positive development for shareholders as it strengthens Lupin's specialty pharmaceutical portfolio, adds a revenue-generating European business, and diversifies beyond its core generics. The 'immediately accretive' nature of the deal could support near-term earnings, while long-term growth depends on successful integration and scaling of the ophthalmology franchise.